Gene Therapy Using Inactive Virus Safely Reduces Muscle Spasticity After Chronic Spinal Cord Injury in Preclinical Study
核心洞察
Researchers used an inactive virus to deliver GABA and VGAT genes directly to spinal cord cells, achieving progressive reduction in spasticity in a rat model of chronic spinal cord injury (搜索).
A single administration produced significant improvements beginning several weeks after treatment, with effects confined to the targeted spinal region.
Safety testing across multiple animal models showed no observable negative effects on motor or sensory function for up to 4.5 years.
A preclinical gene therapy study has demonstrated that delivering therapeutic genes directly to the spinal cord using an inactive virus can produce lasting reductions in muscle spasticity (搜索) following chronic spinal cord injury (搜索). The findings, reported by researchers at UC San Diego, suggest that a single administration may provide long-term relief from a condition that currently requires ongoing treatment and is often accompanied by side effects.
Muscle spasticity (搜索) is a common and often debilitating consequence of spinal cord injury (搜索) that can significantly affect mobility and quality of life. The condition causes muscles to become abnormally stiff or tight due to disrupted nerve signaling, often resulting in exaggerated reflexes, involuntary muscle spasms, and difficulty with movement. Current treatments can help manage symptoms, but they typically require repeated administration and may be associated with adverse effects.
Targeting GABA Signaling to Restore Motor Control
The gene therapy approach targets gamma-aminobutyric acid (GABA) (搜索), a neurotransmitter that helps dampen nerve activity, along with the GABA-releasing machinery known as VGAT (vesicular GABA transporter) (搜索). Previous research has established that spinal cord injury (搜索) can reduce GABA signaling, which contributes to the overactive nerve circuits that drive muscle spasticity (搜索). By restoring both GABA and the cellular machinery needed to release it, the therapy aims to rebalance the disrupted signaling pathways at their source.
Using a rat model of chronic spinal cord injury (搜索)-induced spasticity, the researchers employed an inactive virus as a delivery vehicle to carry the therapeutic genes into spinal cord cells around the injury site. This localized approach is designed to provide a long-lasting effect from a single treatment while targeting only the affected region of the spinal cord, minimizing the potential for off-target effects.
Progressive Improvement and Restored Reflex Function
Animals treated with the therapy showed a progressive reduction in spasticity, with significant improvements observed beginning several weeks after treatment. Beyond simply reducing muscle stiffness, the therapy also partially restored normal spinal reflex function and increased expression of the therapeutic genes within spinal neurons involved in motor control. These findings indicate that the approach addresses the underlying neural circuitry dysfunction rather than merely suppressing symptoms.
Long-Term Safety Profile Across Multiple Models
The researchers extended their investigation by testing the treatment for safety in several other animal models. Critically, the treatment vehicles remained confined to the targeted spinal cord region and caused no observable negative effects on motor or sensory function for up to 4.5 years. This extended safety window provides encouraging evidence that the localized gene therapy approach may avoid the systemic complications that can limit other therapeutic strategies.
The findings suggest that a single administration of spinal segment-targeted gene therapy may provide a long-lasting strategy for reducing muscle spasticity (搜索) caused by spinal cord injury (搜索). The researchers also note that the approach could potentially extend to other neurological conditions associated with abnormal muscle tone, though further studies would be needed to explore those applications.